07630.HK
Impact Therap-b
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 15.59
+4.07%Income statement
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | 9.9M | 5.3M | 4.7M | 33.3M |
| Cost of Revenue | 2.0M | 842.2K | 1.1M | 1.1M |
| Gross Profit | 8.0M | 4.5M | 3.5M | 32.1M |
| Operating Expenses | ||||
| R&D Expense | 52.1M | 25.1M | 27.1M | 30.3M |
| SG&A Expense | 16.7M | 11.5M | 5.4M | 5.8M |
| General & Admin Expense | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | 68.9M | 36.5M | 32.5M | 36.1M |
| Cost and Expenses | 70.8M | 37.4M | 33.7M | 37.3M |
| Operating Income (EBIT) | (60.9M) | (32.0M) | (29.0M) | (4.0M) |
| Non-Operating | ||||
| Interest Income | 2.3M | 953.8K | 1.3M | 803.8K |
| Interest Expense | 17.3M | 9.6M | 7.8M | 80.8K |
| Net Interest Income | (15.0M) | (8.6M) | (6.4M) | 723.0K |
| Other Non-Op Income/Expense | (15.7M) | (9.2M) | (6.6M) | 1.2M |
| Non-Operating Income (excl Interest) | (1.4M) | — | (1.2M) | (1.3M) |
| EBT (Pre-Tax Income) | (76.6M) | (41.2M) | (35.5M) | (2.8M) |
| Income Tax Expense | 559.41 | 139.32 | 418.55 | — |
| Bottom Line | ||||
| Net Income | (76.6M) | (41.2M) | (35.5M) | 519.7K |
| Earnings from Cont. Ops | (76.6M) | (41.2M) | (35.5M) | (2.8M) |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (76.6M) | (41.2M) | (35.5M) | 519.7K |
| Per Share | ||||
| Basic EPS | (HK$0.34) | (HK$0.15) | (HK$0.18) | HK$0.00 |
| Diluted EPS | (HK$0.34) | (HK$0.15) | (HK$0.18) | HK$0.00 |
| Revenue Per Share | HK$0.04 | HK$0.02 | HK$0.02 | HK$0.23 |
| Shares | ||||
| Basic Shares Outstanding | 276.2M | 276.2M | 200.5M | 147.4M |
| Diluted Shares Outstanding | 276.2M | 276.2M | 200.5M | 147.4M |
| Profitability Metrics | ||||
| EBITDA | (58.0M) | (31.4M) | (26.9M) | (1.6M) |
| D&A | 1.5M | 623.3K | 928.4K | 1.1M |
| EBIT | (59.5M) | (32.0M) | (27.8M) | (2.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025